Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific shares gain as Vortex makes commercialisation progress

Vortex updated on progress with its CTC capture system
NetScientific shares gain as Vortex makes commercialisation progress
cancer cells

NetScientific plc (LON:NSCI) shares nudged higher as it revealed portfolio company Vortex Biosciences had moved closer to selling its circulating tumour cell (CTC) capture system in the USA and Europe.

Vortex has registered a Class I medical device with the US FDA (Food and Drug Administration) and established a CE Mark for the proprietary technology.

NetScientific's chief executive and chairman of Vortex, Francois Martelet, said: "Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US."

The CE Mark allows Vortex to install systems in the European Economic Area (EEA).

It will initially be distributed for research use only. The FDA Class 1 registration is a first step towards the sale of the system in the clinical market

The Vortex VTX-1 liquid biopsy system is a fully automated benchtop system for collecting intact CTCs.

CTCs, shed by cancer tumors, can potentially allow for better characterisation of the disease, resulting in better treatment decisions.

Cancer cells are traditionally obtained through tissue biopsies but these are costly, painful, often not possible.

Shares added 6.3% to stand at 67.5p.

Giles_55af4ddca6481.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
dimerix-CEO-Kathy-Harrisson-757.png
Thu
Dimerix Limited has recently received an R&D tax refund.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use